ReShape Lifesciences Inc. (RSLS) Reports Q2 Loss of $0.06/sh

ReShape Lifesciences Inc. (NASDAQ: RSLS) reported Q2 EPS of ($0.06), versus ($1.08) reported last year. Revenue for the quarter came in at $1.97 million, versus $2.25 million reported last year.

For earnings history and earnings-related data on ReShape Lifesciences Inc. (RSLS) click here.

You May Also Be Interested In

• SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
• Disc Medicine (IRON) Reiterated at Overweight by Cantor Fitzgerald on Selcodebart Potential
• Palo Alto Networks (PANW) PT Raised to $430 at Scotiabank